+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy



Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy



Annals of Surgery 257(1): 114-120



After curatively intended surgery for colorectal liver metastases, liver recurrences occur in more than 60% of patients, despite the administration of adjuvant systemic chemotherapy. The aim of this study was to assess the benefit of combined adjuvant hepatic arterial infusion (HAI) and intravenous (IV) 5-FU compared with standard modern adjuvant IV chemotherapy in patients at high risk of hepatic recurrence. From January 2000 to December 2009, 98 patients, who had undergone curative resection of at least 4 colorectal liver metastases, were selected from a prospective database. Among them, 44 (45%) had received postoperative HAI combined with systemic 5-FU (HAI group) and 54 (55%) had received "modern" systemic chemotherapy (IV group). The 2 groups were similar in terms of age, sex, the stage of the primary, and the administration of preoperative chemotherapy. The median number of HAI cycles received per patient was 7 [range, 1-12]. Twenty-nine patients (66%) had received at least 6 cycles of HAI oxaliplatin, and 22 patients (50%) had received the full planned treatment. For the remaining 22 patients (50%), HAI chemotherapy had been discontinued because of toxicity (n = 8), HAI catheter dysfunction (n = 6), an early recurrence (n = 6), and patient's refusal (n = 2). After a median follow-up of 60 months (51-81 months), 3-year overall survival was slightly higher in the HAI group (75% vs 62%, P = 0.17). Three-year disease-free survival was significantly longer in patients in the HAI group than those in the IV group (33% vs 5%, P < 0.0001). In the multivariate analysis, adjuvant HAI chemotherapy and an R0 resection margin status were the only independent predictive factors for prolonged disease-free survival. Postoperative HAI oxaliplatin combined with systemic chemotherapy after curatively intended surgery of colorectal liver metastases is feasible and may significantly improve disease-free survival of patients at high risk of hepatic recurrence compared with adjuvant modern systemic chemotherapy alone. These results should be confirmed in a randomized study.

(PDF emailed within 0-6 h: $19.90)

Accession: 051383406

Download citation: RISBibTeXText

PMID: 23235397

DOI: 10.1097/SLA.0b013e31827b9005


Related references

Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case-Control Study. Annals of Surgical Oncology 24(1): 150-158, 2016

Clinical results of pharmacokinetic modulating chemotherapy (PMC) in combination with hepatic arterial 5FU infusion, continuous venous 5FU infusion and oral UFT as adjuvant chemotherapy after liver resection for hepatic colorectal metastases. Journal of Clinical Oncology 23(16_suppl): 3665-3665, 2016

Hepatic arterial infusion chemotherapy with oxaliplatin in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(12): 2594-2597, 2011

Intermittent hepatic arterial infusion of high-dose fluorouracil on a weekly schedule as adjuvant chemotherapy following curative resection of colorectal liver metastases: a randomized study. Journal of Clinical Oncology 23(16_suppl): 3727-3727, 2016

Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. Journal of Clinical Oncology 23(22): 4888-4896, 2005

Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial. Bmc Cancer 19(1): 327, 2019

Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer. Annals of Surgical Oncology 10(4): 348-354, 2003

Adjuvant hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases. American Journal of Surgery 166(6): 743-6; Discussion 746-8, 1993

Efficacy of adjuvant hepatic arterial infusion chemotherapy following resection of colorectal liver metastases. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 26(12): 1698-1701, 1999

Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973). Bmc Cancer 18(1): 787, 2018

A pilot study of adjuvant hepatic arterial infusion chemotherapy, associating 5-fluorouracil and leucovorin, after resection of colorectal cancer liver metastases. Surgical Oncology 4(6): 317-322, 1995

Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. Journal of Clinical Oncology 29(7): 884-889, 2011

A randomized phase III study of hepatic arterial infusion chemotherapy with 5-fluorouracil and subsequent systemic chemotherapy versus systemic chemotherapy alone for colorectal cancer patients with curatively resected liver metastases (Japanese Foundation for Multidisciplinary Treatment of Cancer 32). Journal of Cancer Research and Therapeutics 14(Supplement): S761-S766, 2018

Study of hepatic arterial infusion chemotherapy for prophylaxis of liver metastases of colorectal cancer after hepatic resection. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(11): 1497-1499, 1995

Hepatic arterial chemotherapy in combination with systemic chemotherapy compared with hepatic arterial chemotherapy alone for liver metastases from colorectal cancer: results of a multi-centric randomized study. In Vivo 20(6a): 707-709, 2007